Abatacept versus hydroxychloroquine for prevention of rheumatoid arthritis in individuals with palindromic rheumatism: a randomized open-label trial

A study published in Nature Medicine on May 14, 2026, found that subcutaneous injections of abatacept are more effective than oral hydroxychloroquine in preventing the progression to persistent arthritis in individuals with palindromic rheumatism.

The research was conducted as a randomized open-label trial to compare the efficacy of these two interventions in patients experiencing the episodic joint inflammation associated with palindromic rheumatism.

Palindromic rheumatism is a condition characterized by sudden episodes of joint inflammation that typically resolve quickly and migrate from one joint to another. A significant clinical challenge for patients with this condition is the risk of the disease progressing into a persistent form of arthritis, such as rheumatoid arthritis.

The trial results indicate that participants receiving subcutaneous abatacept had a lower rate of progression to persistent arthritis than those treated with oral hydroxychloroquine.

Treatment Mechanisms and Clinical Context

Abatacept is a medication that targets the immune system to reduce inflammation. It works by interfering with the activation of T cells, which are a type of white blood cell central to the immune response. By modulating these cells, the medication helps to limit the inflammatory activity that can lead to joint destruction.

Hydroxychloroquine is an oral medication commonly used in the management of various rheumatic and autoimmune disorders. It is often utilized to control symptoms and slow the progression of inflammatory joint diseases.

The goal of treating palindromic rheumatism is to manage the acute episodes of swelling and pain while preventing the transition to a chronic, persistent arthritic state. The transition to persistent arthritis often involves more severe and continuous joint damage, which can lead to permanent loss of mobility and joint deformity.

The findings from the May 14, 2026, report suggest that a T-cell modulating approach via subcutaneous injection may provide superior protection against this progression compared to the traditional oral therapy of hydroxychloroquine.

Because the trial was open-label, both the investigators and the participants were aware of the treatment assignments. This design is common in certain clinical trials but is noted as a factor in how the data is interpreted.

The results highlight the potential for targeted biological therapies to alter the disease trajectory in patients with episodic rheumatic conditions, potentially reducing the long-term burden of persistent joint disease.